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Breast cancer is the most common cause of cancer-related death worldwide, thus remaining a crucial health problem among
women despite advances in conventional therapy. Therefore, new alternative strategies are needed for effective diagnosis and
treatment. One approach is the use of oncolytic viruses for gene-directed enzyme prodrug therapy. Here, the lacZ-carrying vaccinia
virus (VACV) strain GLV-1h68 was used in combination with a b-galactosidase-activatable prodrug derived from a seco-analog of
the natural antibiotic duocarmycin SA. Tumor cell infection with the VACV strain GLV-1h68 led to production of b-galactosidase,
essential for the conversion of the prodrug to the toxic compound. Furthermore, drug-dependent cell kill and induction of the
intrinsic apoptosis pathway in tumor cells was also observed on combination therapy using the prodrug and the GLV-1h68 strain,
despite the fact that VACV strains encode antiapoptotic proteins. Moreover, GI-101A breast cancer xenografts were effectively
treated by the combination therapy. In conclusion, the combination of a b-galactosidase-activatable prodrug with a tumor-specific
vaccinica virus strain encoding this enzyme, induced apoptosis in cultures of the human GI-101A breast cancer cells, in which a
synergistic oncolytic effect was observed. Moreover, in vivo, additional prodrug treatment had beneficial effects on tumor
regression in GLV-1h68-treated GI-101A-xenografted mice.
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Introduction
Breast cancer is the most common form of cancer and the
second most common cause of cancer-related death in
women.
1 In the United States of America, it is estimated
that 1.5 million new cases of breast cancer was diagnosed
in 2009, and that B40400 women will die from breast
cancer-related causes alone, despite advances in conven-
tional therapy.
2 Consequently, novel, well-tolerated
and more effective therapies are needed to reduce the
number of breast cancer-related deaths. Among several
strategies to improve currently applied treatments, the use
of oncolytic viruses is a very promising therapeutic
approach.
3,4
Regarding the many different oncolytic viral agents
used for tumor-directed therapy, vaccinia virus (VACV)
has several advantages. This large DNA virus exclusively
replicates in the cytoplasm without the need for host
DNA-synthesis machinery, thereby excluding the risk of
integration into the host genome. It displays rapid spread,
a broad range of host cell tropism and a high capacity for
genetic payload, with up to 25kb of foreign DNA.
5
Moreover, the systemic injection of recombinant VACV
(rVACV) strains into tumor-bearing mice resulted in high
viral titers in tumors, but not in other organs, indicating
tumor-specific colonization.
6–8
Another approach is the use of viruses for gene-directed
enzyme prodrug therapy (GDEPT) to improve the
selectivity of chemotherapy by enabling cancer cells to
convert prodrugs of low cytotoxictiy to highly potent
drugs. Because the suicide genes must be expressed
selectively in tumor cells to prevent adverse effects in
the patient, substantial efforts have been conducted to
develop gene transfer vectors specifically targeting tu-
mors. Among these, tumor-specific viruses including
adenovirus, sindbis virus, retroviruses, herpes simplex
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to be the best-suited gene transfer vectors (reviewed in
Schepelmann and Springer
9). Using the VACV species,
several promising results have already been obtained with
replication-competent, cytosine deaminase-expressing
VACV strains in combination with the well-described
prodrug 5-fluorocytosine.
10–14 Here, a b-galactosidase-
expressing VACV strain was used for GDEPT.
The b-galactosidase-encoding lacZ gene of E. coli was
the first widely used reporter gene. It has numerous
applications in molecular and cellular biology and has
also been used as marker in clinical trials.
15,16 Moreover,
a variety of substrate structures were generated to enable
detection of b-galactosidase expression in live animals, by
optical imaging with near-infrared fluorescent probes,
17,18
by luminescent imaging using a caged D-luciferin–galacto-
side conjugate,
19 with radionuclide substrates for SPECT
imaging
20 and with probes enabling magnetic resonance
imaging.
21 As prodrug-mediated tumor therapy has been
investigated more extensively, a number of b-galactosi-
dase-activatable prodrugs have also been described, the
most promising of which are the seco-analogs of the
highly cytotoxic natural antibiotics CC-1065 and duocar-
mycin SA (for a recent review see Tietze and Krewer
22).
However, no experiments have been published in the
literature that describes the successful use of these
prodrugs in live tumor-bearing animal studies. One of
the most promising prodrugs developed so far, namely,
the (1S)-seco-CBI-DMAI-b-D-galactoside 1, showed a
high Q IC50 value (Q IC50¼IC50 of prodrug/IC50 of
prodrug in the presence of the cleaving enzyme, with IC50
being the concentration required for 50% growth inhibi-
tion of target cells) of 3500 and an IC50 value for the
corresponding highly cytotoxic drug 2 of 16pM (Supple-
mentary Figure S1).
23 In this study, this prodrug, in
combination with the b-galactosidase-encoding oncolytic
VACV strain GLV-1h68, was tested in cell culture and
animals, resulting in enhanced breast cancer regression.
Materials and methods
Cell culture and VACV constructs
The GI-101A human breast cancer cells were cultured in
RPMI-1640 medium containing 1% HEPES (4-(2-hydro-
xyethyl)-1-piperazineethanesulfonic acid), 1% sodium
pyruvate, 1% antibiotic–antimycotic solution and 20%
fetal bovine serum (FBS). The human adenocarcinoma
cells MDA-MB-231-CBG (click-beetle luciferase-expres-
sing cells derived from MDA-MB-231; U Donat et al.,
unpublished data) were cultured in Dulbecco’s modified
Eagle’s medium, 10% FBS and 10mgml
 1 blasticidin.
Canine breast adenoma ZMTH3 cells were cultured in
RPMI-1640 medium containing 20% FBS.
GLV-1h68 was derived from VACV LIVP as described
previously.
7 In GLV-1h43, the lacZ-containing gene
cassette was replaced by a nonrelevant gene-containing
cassette. Both strains were developed from the VACV
LIVP strain by site-directed insertional mutagenesis. The
F14.5L locus was replaced by insertion of a Renilla
luciferase–GFP (green fluorescent protein) fusion con-
struct under the control of a synthetic early/late promoter
(PSEL). The hemagglutinin (HA) gene was replaced by the
b-glucuronidase-encoding gene gusA and placed under the
control of the late promoter P11. The viral thymidine
kinase (TK) was either replaced by lacZ, the gene encoding
b-galactosidase, controlled by the VACV early/late P7.5
promoter in GLV-1h68, or by a nonrelevant gene construct
in GLV-1h43 (Figure 1a). The virus strains GLV-1h71 and
Figure 1 Recombinant vaccinia virus (rVACV) constructs and
marker gene expression. (a) The wild-type LIVP was used for the
generation of modified rVACV with designations of GLV-1h43 and
GLV-1h68. P11, VACV late P11 promoter; PE/L, VACV synthetic
early/late promoter; P7.5, VACV 7.5K early/late promoter.
(b) Expression of the marker gene green fluorescent protein (GFP)
could be detected in plaques of both virus strains, whereas staining for
X-gal revealed expression of b-galactosidase in GLV-1h68-infected
GI-101A cells only. HA, hemagglutinin; TK, thymidine kinase.
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1h68 and GLV-1h43, respectively.
Infections of cell cultures
At 2 days before infection, cells were seeded in six-well
plates for RNA and protein isolation, and in 24-well
plates for survival and microscopy studies. If not
otherwise indicated, the 90% confluent cell layer was
mock infected or infected with GLV-1h43 or GLV-1h68
at a multiplicity of infection per cell of 0.05 or 0.5 for 1h
at 371C in medium containing 2% FBS. The virus-
containing medium was then aspirated and replaced by
non-prodrug-containing cell culture medium or medium
supplemented with 10nM of prodrug.
Isolation and detection of proteins
At 6, 12, 24, 48 or 72h post-infection (hpi), cells were
harvested and lysed in SDS sample buffer or in lysis
buffer (10mM Tris (pH 7.4), 150mM NaCl, 1mM EDTA,
10mM HEPES, 0.05% Igepal and 0.75mM dithiothreitol)
supplemented with a proteinase inhibitor cocktail (Roche,
Penzberg, Germany). The cell lysates were separated on a
10, 12 or 15% SDS-polyacrylamide electrophoresis gel,
and proteins were transferred onto a nitrocellulose
transfer membrane (Whatman GmbH, Dassel, Germany).
The membrane was then incubated with one of the
following: anti-b-actin mouse monoclonal antibody
(ab6276, Abcam, Cambridge, UK), anti-b-galactosidase
rabbit polyclonal antibody (A-11132, Molecular Probes,
Leiden, the Netherlands), anti-cleaved caspase-3 rabbit
polyclonal antibody (no. 9661, Cell Signaling Technology,
Danvers, MA), anti-full-length caspase-3 rabbit polyclo-
nal antibody, (no. 9662, Cell Signaling Technology), anti-
caspase-8 mouse monoclonal antibody (no. 9746, Cell
Signaling Technology), anti-caspase-9 rabbit polyclonal
antibody (no. 9502, Cell Signaling Technology), anti-GFP
rabbit polyclonal (sc-8334, Santa Cruz, Heidelberg,
Germany) or anti-cleaved poly (ADP-ribose) polymerase
(PARP) mouse monoclonal antibody (51-9000017, BD
Pharmingen, Heidelberg, Germany). The first antibodies
were then detected using horseradish peroxidase-labeled
anti-mouse (ab6728, Abcam) or anti-rabbit (ab6721,
Abcam) secondary antibodies, followed by enhanced
chemiluminescence.
Quantitative results were obtained using a NightOWL
LB 981 imaging system (Berthold Technologies, Bad
Wildbad, Germany).
Analysis of RNA expression
At 6, 12, 24, 48 or 72hpi, cellular RNA was isolated using
the RNeasy Mini Kit (Qiagen, Hilden, Germany),
followed by DNase treatment using DNA-free Kit
(Ambion, Austin, TX). RNA samples were converted to
cDNA by RevertAid First Strand cDNA Synthesis Kit
(Fermentas, St Leon-Rot, Germany) and analyzed by
reverse transcriptase PCR and quantitative PCR using
primers for glyceraldehyde 3-phosphate dehydrogenase
(from First Strand cDNA Synthesis Kit (Fermentas)); for
b-actin, the primers used were forward: 50-GGAGAA
AATCTGGCACCACAC-30 and reverse: 50-CCATCTCT
TGCTCGAAGTCCA-30; for lacZ, forward: 50-GGC
CAGTTGCGTGACTACC-30 and reverse: 50-CCGACA
TCGCAGGCTTCTG-30 for real-time PCR and 50-CAC
GGCATTAAAGTTGTTCTGCTTC-30 for reverse tran-
scriptase PCR; and for GFP, forward: 50-GCGTG
CAGTGCTTTTCCAG-30 and reverse: 50-AGGGCAGA
CTGGGTGGAC-30.
Quantitative PCR was performed using ABsolute QPR
SYBR Green Mix (Thermo Scientific, Epsom, UK) in a
DNA Engine Opticon CFD-0200 (MJ Research, Wal-
tham, MA) and analyzed using the Opticon Monitor
software (MJ Research).
b-Galactosidase assays and X-gal staining
The concentration of cell-associated b-galactosidase, as well
as the concentration in the supernatant, was analyzed in a b-
galactosidase assay. A standard dilution series was per-
formed over the range of 1 10
 6–1Uml
 1 b-galactosidase
(from Aspergillus oryzae—11.2Umg
 1, G5160, Sigma-Al-
drich, Steinheim, Germany). Tumor homogenates, blood
serum samples, cell lysates and cell culture supernatants
were incubated with the staining solution (40ml X-gal
in dimethylformamide (40mgml
 1), ferricyanide (12mM
K3Fe(CN)6), 5.2mM MgCl2 and ferrocyanide solution
(12mM K4Fe(CN)6)), and optical density was determined
in a Tecan sunrise absorbance reader (Tecan, Crailsheim,
Germany).
For X-gal staining, cells on coverslips or tumor sections
were incubated with the staining solution overnight at
room temperature, washed several times with PBS and
mounted in 80% glycerol in PBS.
Histology and fluorescent microscopy
For the microscopical analysis of b-galactosidase and
GFP expression, GI-101A cells were seeded on coverslips
and infected using 100 plaque-forming units (PFUs) per
well. After 2 days, cells were fixed for 2min using 4%
paraformaldehyde and washed in PBS. Subsequently,
either direct visualization was performed for GFP or
b-galactosidase staining was carried out before micro-
scopical analysis by means of a Leica DMR fluorescence
microscope (Leica, Wetzlar, Germany) and a Diagnostic
Instruments digital camera model 2.3.1 (Visitron Systems
GmbH, Puchheim, Germany) using Meta-Vue 5.0r2
software (Visitron Systems GmbH).
Histology and fluorescence microscopy of tumor
sections were performed as described previously.
24
Briefly, snap-frozen GI-101A tumors of GLV-1h43- or
GLV-1h68-injected mice were fixed in 4% paraformalde-
hyde and 100mm vibratome tissue sections were permea-
bilized in PBS containing 0.3% Triton X-100. Neigh-
boring sections were then stained using X-gal and
Hoechst 33342. After several rinses in PBS, tissue sections
were incubated in PBS containing 60% (v/v) glycerol and
then mounted in PBS containing 80% (v/v) glycerol.
Tumor specimens were examined with the Stereo-
Fluorescence microscope (MZ16 FA, Leica, Heerbrugg,
Switzerland) equipped with a digital CCD camera
(DC500, Leica). The blue b-galactosidase staining was
visualized using white light, whereas GFP and Hoechst
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(1300 1030pixel color images) were processed with
Photoshop 10.0 (Adobe Systems, San Jose, CA) and
merged to yield pseudocolored pictures.
Prodrug synthesis
Prodrug synthesis was performed as described pre-
viously
23 and stock solutions of the prodrug were
prepared in dimethyl sulfoxide.
Cell viability assay
The amount of viable cells after infection with GLV-1h43 or
GLV-1h68 and/or treatment with 10nM prodrug
was measured using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-
tetrazolium bromide (MTT) (Sigma, Taufkirchen,
Germany). At the indicated time points, the medium was
replaced by 0.5ml MTT solution at a concentration of
2.5mgml
 1 MTT dissolved in RPMI 1640 medium without
phenol red and incubated for 4h at 371Ci na5 %C O 2
atmosphere. After removal of the MTT solution, 1 N HCl
diluted in 2-propanol was added and the optical density was
then measured at a wavelength of 570nm. Mock-infected cells
served as a reference and were considered as 100% viable.
The rate of apoptosis was determined using the PE-
annexin V apoptosis detection kit (BD Biosciences,
Heidelberg, Germany) according to the manufacturer’s
instructions. The analysis was performed on a Epics XL
flow cytometer (Beckman Coulter GmbH, Krefeld,
Germany) and the data were analyzed using WinMDI
2.8 (Joe Trotter, Scripps Research Institute, La Jolla, CA).
Animal studies
GI-101A xenograft tumors were developed in 6- to 8-week-
old female nude mice (NCI:Hsd:Athymic Nude-Foxn1
nu,
Harlan, Borchem, Germany and Indianapolis, IN) by
implanting 5 10
6 GI-101A cells subcutaneously on both
hind flanks (two tumors per mouse). Tumor growth was
recorded once a week in two dimensions using a digital
caliper. Tumor volume was calculated as ((length width
2)/2)
a n dr e p o r t e di nm m
3.A t3 0d a y sa f t e rt u m o rc e l l
implantation, three groups of 12 mice were injected with
a single intravenous dose of PBS, or 5 10
6PFUs of
GLV-1h43 or GLV-1h68 in 100mlo fP B S .T h e1 2m i c eo f
each group were subdivided into two groups of six mice that
were intraperitoneally injected three times a week with 200ml
of a 1:1 (v/v) mixture of dimethyl sulfoxide and PBS alone or
200ml of the same mixture containing prodrug (100nM),
starting 6 days after VACV injection.
All animal experiments were carried out in accordance
with protocols approved by the Institutional Animal Care
and Use Committee of Explora Biolabs (San Diego, CA) or
the ‘Regierung von Unterfranken’ (Wu ¨ rzburg, Germany).
Statistical analysis
The significance of differences between the various groups
was determined using a two-tailed unpaired t-test (Excel
2008 for Mac, Microsoft, Redmond, WA). A P-value
o0.05 was considered significant.
Results
b-Galactosidase-activatable prodrug: mechanism
of action
The recently described seco-duocarmycin SA analog-
derived prodrug 1 (Supplementary Figure S1) used in
this study was previously shown to be extremely efficient
in killing cells in culture.
23 On b-galactosidase activation,
prodrug 1 releases a drug with an IC50 value of 16pM that
is 3500 times more cytotoxic than the prodrug itself.
However, studies have not yet determined whether target
cell death also occurred via the same intrinsic apoptosis
mechanism as already described for duocarmycin SA.
25–27
We therefore incubated GI-101A cells with PBS and
prodrug alone or prodrug in combination with purified
b-galactosidase. In contrast to PBS or prodrug-only treated
cells, Hoechst 33342 staining showed nuclear condensation
in a high proportion of prodrug and b-galactosidase-treated
cells. A parallel staining with propidium iodide, which is
only permeant into dead cells, was mostly negative. This
indicated an intact cell membrane and supported the notion
of apoptosis induction (data not shown).
To validate that the apoptosis was induced, cellular
proteins were harvested and analyzed by western blotting
using antibodies against cleaved PARP, caspase-3,
caspase-8 and caspase-9 (Figure 2). It was obvious that
cleaved PARP and cleaved caspase-3, as indicators for
apoptosis,
28 were only detectable in cells that were treated
with the prodrug in combination with b-galactosidase, but
absent in PBS and prodrug-only controls. Furthermore,
Figure 2 Validation of apoptosis induction on prodrug activation.
Western blot analysis with antibodies against cleaved poly (ADP-
ribose) polymerase (PARP), full-length (FL) caspase-3, cleaved (CL)
caspase-3, full-length caspase-9, full-length caspase-8 and b-actin.
Cleaved PARP and cleaved caspase-3, as indicators for apoptosis,
were only detectable in both prodrug and b-galactosidase-treated
cells. Additionally, full-length caspase-9 concentration significantly
decreased because of treatment with prodrug and b-galactosidase,
whereas caspase-8 remained uncleaved. Equal protein loading was
confirmed by detection of b-actin.
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full-length caspase-9 dropped significantly in prodrug and
b-galactosidase-treated cells, indicating that apoptosis is
induced via the intrinsic rather than extrinsic pathway.
29,30
Characterization of rVACV strains GLV-1h68
and GLV-1h43 in cell culture
To test the expression of the reporter proteins Ruc-GFP and
b-galactosidase, the human breast cancer cell line GI-101A
was infected with the rVACV strains GLV-1h68 or GLV-
1h43 (Figure 1a). As previously mentioned, b-galactosidase
was used as a prodrug-activating protein in this study.
As expected, expression of GFP could be observed for
both strains by fluorescence microscopy, whereas b-
galactosidase-specific X-gal staining of plaques was only
positive in GLV-1h68-infected GI-101A cells (Figure 1b).
Reverse transcriptase PCR analysis (Figure 3a) and
western blotting (Figure 3b) confirmed the virus-mediated
expression of the reporter genes. No Ruc-GFP- or lacZ-
specific transcripts or proteins could be detected in
mock-infected control cells, whereas both were detectable
in GLV-1h68-infected cells. In contrast, infection
with GLV-1h43 led to production of Ruc-GFP but not
b-galactosidase. Although reporter gene transcripts
could be detected as early as 6hpi, the respective proteins
were not detected by western blot until 12hpi. In
addition, real-time PCR revealed an increasing lacZ
expression until 48hpi (data not shown), correlating with
the western blot analysis (Figure 3b) of GLV-1h68-
infected cells.
As the prodrug is converted only by a functional
enzyme, we also determined the b-galactosidase activity in
cell lysates (Figure 3c) and supernatants (Figure 3d) of
mock-, GLV-1h43- and GLV-1h68-infected GI-101A
cells. The enzyme activity increased until 48hpi in the
cell lysates, as supported by the western blot results
(Figure 3b). In supernatants, no b-galactosidase activity
was detected by 12hpi, but then increased by 72hpi,
probably as a consequence of increased viral cell lysis. In
mock- or GLV-1h43-infected cells, no b-galactosidase
activity was detectable at any time points.
Furthermore, when coincubating the cell lysates and
supernatants of mock-, GLV-1h43- or GLV-1h68-in-
fected cells with uninfected GI-101A cells, the observed
prodrug-mediated cell death correlated with the presence
of active b-galactosidase (Supplementary Figure S2).
Therefore, a b-galactosidase-specific prodrug should
only be activated on GLV-1h68 infection.
Figure 3 Evaluation of reporter gene expression after infection with recombinant vaccinia virus (rVACV). (a) Reverse transcriptase PCR results
from mock-infected cells (untreated), GLV-1h68- (68) or GLV-1h43 (43)-infected cells at 6, 12, 24, 48 and 72hpi using lacZ-, green fluorescent
protein (GFP)- and glyceraldehyde 3-phosphate dehydrogenase-specific primers. Infection with GLV-1h68 led to production of Ruc-GFP and
lacZ-specific transcripts as early as 6hpi, whereas in GLV-1h43-infected cells, no lacZ transcript could be detected. Both reporter gene
transcripts were not detectable in mock-infected cells. (b) Western blot analysis using b-galactosidase (b-gal) and Ruc-GFP-specific antibodies,
showing no expression of b-galactosidase in GLV-1h43-infected cells. In contrast, both proteins could be detected in GLV-h168-infected cells
after 12hpi. b-galactosidase expression increased up to 48hpi. Equal protein loading was confirmed by detection of b-actin. (c, d) Determination
of b-galactosidase activity in cell lysates (c) and supernatants (d) after infection with GLV-1h43, GLV-1h68 and mock infection. Enzyme activity in
cell lysates increased up to 48hpi with GLV-1h68, further supporting the western blot results. In supernatants, no active enzyme could be
detected until 12hpi, but then increased until 72hpi. As expected, no active enzyme could be detected in mock- or GLV-1h43-infected cells or
supernatants at all time periods. PBS, phosphate-buffered saline.
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due to prodrug addition
In tumors treated with oncolytic VACV, not every cell is
infected and will express b-galactosidase; hence, sufficient
prodrug bystander effects are needed for enhancement of
oncolysis.
11
We therefore chose to use a low multiplicity of infection
of 0.05 for experiments, applying the prodrug directly in
combination with mock-, GLV-1h43- and GLV-1h68-
infected cells. The prodrug was added at a concentration
of 10nM immediately after infection. Non-prodrug-
treated cells served as controls. Cell survival was analyzed
by MTT assays on days 3 and 7 after infection.
As shown in Figure 4, on day 3 post-infection, no
significant difference was observed between prodrug-
treated or untreated mock-, GLV-1h43- or GLV-1h68-
infected cells. Conversely, simultaneous treatment of GI-
101A cells with GLV-1h68 and 10nM of prodrug resulted
in significantly higher tumor cell killing at 7 days post-
infection compared with GLV-1h68 alone. The prodrug
alone had some inhibitory effects on mock- or GLV-1h43-
infected GI-101A cells, resulting in an B30% reduction of
cell numbers on day 7 post-infection, when compared
with the respective non-prodrug-treated controls.
However, only the combination of the prodrug with
GLV-1h68 resulted in strong synergistic effects and the
most efficient cell killing (Figure 4, inset).
Similar effects were also observed when using
other breast tumor cells such as the human breast
adenocarcinoma cells MDA-MB-231-CBG and canine
breast adenoma ZMTH3 (data not shown).
Induction of apoptosis in GLV-1h68-infected tumor
cells after addition of prodrug
VACV encodes a number of antiapoptotic factors and
inhibits both the extrinsic as well as the intrinsic apoptotic
pathway (reviewed in Taylor and Barry
31). To test
whether these factors can also prevent cells from
(pro)drug-mediated apoptosis, we analyzed the induction
of apoptosis by measuring the binding of labeled annexin
V using flow cytometry. As both GLV-1h68 and
GLV-1h43 result in very high expression levels of the
fusion protein Ruc-GFP, which interfered with the flow
cytometry measurements, we used two other VACV
strains, namely GLV-1h71 (b-galactosidase-positive) and
GLV-1h85 (b-galactosidase-negative), which do not
express the fluorescent protein. At 3 days post-infection,
we detected 59.9±1.1% annexin V-positive cells in
prodrug-treated cells infected with GLV-1h71, but only
39.9±4.4% cells when GLV-1h85 was used. This
corresponded well with 40.2±1.9% apoptotic cells in
GLV-1h71-infected cells that were not treated with
Figure 4 Cell survival studies after prodrug treatment and infection.
Cells were infected with a low multiplicity of infection of 0.05 or mock
infected and treated with 10nM prodrug. Non-prodrug-treated cells
served as the control. Cell viability was determined by 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)-assays
on days 3 and 7 post-infection. On day 3 post-infection, no significant
difference in cell viability between the different samples was
observed. Combined treatment of cells with GLV-1h68 and prodrug
induced a significantly higher tumor cell kill 7 days post-infection
compared with infection with GLV-1h68 alone. Although prodrug
treatment alone as well as rVACV treatment alone had inhibitory
effects when compared with untreated cells (significance not shown),
only simultaneous treatment of cells with GLV-1h68 and prodrug
contributed to strong synergistic effects and the most efficient cell
killing (inset, showing survival of prodrug-treated vs corresponding
untreated cells). In each chart, average plus standard deviation
(n¼3) is shown. Asterisk indicates statistical significance (Po0.05).
PBS, phosphate-buffered saline.
Figure 5 Apoptosis induction in GLV-1h68-infected tumor cells on
prodrug treatment. Western blot analysis using specific antibodies
against cleaved poly (ADP-ribose) polymerase (PARP), full-length
(FL) caspase-3, cleaved (CL) caspase-3, full-length caspase-9 and
b-actin. Samples were taken from infected or mock-infected GI-101A
cells treated (þ) or untreated ( ) with 10nM prodrug. Expression of
the apoptosis indicator PARP was significantly higher in GLV-1h68-
infected cells treated with prodrug, compared with cells treated with
vaccinia virus alone or with GLV-1h43 and prodrug. Uninfected
control cells showed almost no expression of PARP. Furthermore,
approximately no full-length caspase-3 or caspase-9 could be
observed in GLV-1h68-infected cells treated with prodrug, whereas
both proteins were present in the other samples. Cleaved caspase-3
was detectable only in those samples retrieved after combined
treatment with GLV-1h68 and prodrug. Equal loading of protein was
confirmed by detection of b-actin. PBS, phosphate-buffered saline.
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be attributed to the prodrug treatment.
Even clearer results were obtained when analyzing
protein lysates of prodrug-treated or untreated mock-,
GLV-1h43- and GLV-1h68-infected cells, using western
blotting with antibodies against cleaved PARP, caspase-3
and caspase-9 (Figure 5).
The quantitative analysis of the western blots revealed a
sevenfold higher concentration of cleaved PARP in cells
treated with GLV-1h68 in combination with the prodrug,
when compared with cells treated with VACV alone or
with GLV-1h43 and the prodrug. In GI-101A cells not
infected with rVACV, almost no cleaved PARP was
detectable. Even more pronounced was the difference
with cleaved caspase-3, which could only be detected in
GLV-1h68-infected cells treated with prodrug. On the
other hand, an at least threefold less full-length caspase-3
and a sevenfold less full-length caspase-9 was present in
GI-101A cells treated with prodrug after infection with
GLV-1h68 compared with controls. The induction of
apoptosis, therefore, can still be observed in the presence
of VACV and is specifically induced in cells treated with
prodrug and the b-galactosidase-encoding GLV-1h68
strain.
Enhanced GLV-1h68-mediated oncolysis on prodrug
treatment
Next, we investigated the oncolytic potential of a
combined treatment using the b-galactosidase-activatable
prodrug and the rVACV strain GLV-1h68 in the GI-101A
xenograft breast cancer model.
As active b-galactosidase might be released from
GLV-1h68-infected tumors into the blood stream and
lead to unwanted side effects in other tissues, the
b-galactosidase activity in tumors and in blood serum
samples was tested in a preliminary experiment. Three
GI-101A tumor-bearing mice were injected with GLV-
1h68, and at 42 days post-infection, the mice were killed.
Tumor homogenates and blood serum samples were then
analyzed by b-galactosidase assay. The results revealed
high enzyme activity in tumor samples (B100Ug
 1
tumor tissue), but undetectable levels in blood serum
samples (detection limit: 0.3Uml
 1). Therefore, un-
wanted side effects are unlikely to occur. Thus, we began
to determine the effects of the b-galactosidase-activatable
prodrug in combination with the lacZ-encoding GLV-
1h68 strain in live animals.
For this purpose, mice were subcutaneously injected
with 5 10
6 GI-101A cells on each flank, which formed
tumors of around 450mm
3 after 30 days. Groups of 12
mice were then intravenously injected with PBS or with
5 10
6PFUs each of both GLV-1h43 and GLV-1h68
cells. The animals were then subdivided equally into two
groups. At 6 days after rVACV injection, prodrug
treatment was started in one subgroup, whereas the other
subgroup received injections of a 1:1 (v/v) mixture of
dimethyl sulfoxide and PBS only (Figure 6).
Tumor size measurements revealed that both rVACV
strains showed tumor therapeutic efficacy compared with
PBS-injected mice, with the PBS-injected mice having to
be killed because of tumor burden between 6 and 9 weeks
post-injection. Interestingly, GLV-1h43-mediated tumor
therapy was more effective compared with GLV-1h68
treatment. The injection of the prodrug resulted in
reduced tumor size in all subgroups when compared with
the corresponding non-prodrug-treated animals, although
the difference did not reach statistical significance in those
groups injected with PBS or the GLV-1h43 strain
(P40.15). In contrast, the subgroup treated with prodrug
after injection of the lacZ-encoding GLV-1h68 strain had
a significantly decreased tumor volume (Po0.006) at 70
days after rVACV injection, when compared with the
non-prodrug-treated GLV-1h68-injected control. The
tumor size in the prodrug-treated subgroup was reduced
close to the initial tumor volume before injection of
VACV, whereas the non-prodrug-treated subgroup had
an average tumor volume of B930mm
3.
Prodrug treatment: effects on viral tumor colonization
As prodrug conversion and cell killing might lead to
inhibition of viral replication or enrichment of lacZ-
negative mutants of GLV-1h68 within the tumor, both
prodrug-treated and untreated tumors of mice were
isolated 71 days after rVACV injection, and the amount
of virus was determined by standard plaque assay
(Supplementary Figure S3a). No significant differences
(P40.42) were observed between prodrug-treated or
untreated GLV-1h43- and GLV-1h68-injected mice.
Figure 6 Characterization of tumor progression and oncolysis on
recombinant vaccinia virus (rVACV) and prodrug treatment. Groups
of 12 GI-101A tumor-bearing mice (two tumors on each) were
injected intravenously with phosphate-buffered saline (PBS), or
5 10
6PFUs of GLV-1h43 and GLV-1h68. Although one subgroup
of six mice received prodrug treatment, the other subgroup received
injections of 50% dimethyl sulfoxide/50% PBS only. Tumor size was
measured weekly until 70dpi for rVACV-infected mice or until the
mice had to be killed because of tumor burden in PBS-injected
control groups. Injection of prodrug led to reduced tumor size in all
subgroups compared with untreated mice, but reached no statistical
significance except in the GLV-1h68-treated group on day 70 after
rVACV injection. Depicted are average values plus standard
deviation. Asterisk indicates statistical significance (Po0.05) be-
tween prodrug-treated and untreated subgroups.
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used to activate prodrug in cell culture experiments
(Supplementary Figure S3b). For this purpose, lysates
of two tumors per subgroup were diluted in cell culture
medium (resulting in lysate of 20mg tumor tissue in 1ml
cell culture medium). This was then added to GI-101A
cells and MTT assays were performed 2 days later. Added
prodrug was converted and resulted in cell killing
when tumor lysates were derived from mice injected with
GLV-1h68, regardless of previous prodrug treatments in
the living animals. On the other hand, no killing was
observed in non-prodrug-treated GI-101A cells or in
cells that were treated with tumor lysates derived from
GLV-1h43-injected mice.
In addition, adjacent tumor sections of prodrug-treated
GLV-1h43- or GLV-1h68-injected mice were analyzed
for the presence of GFP and b-galactosidase activity
(Supplementary Figure S3c). Both viral constructs led to
large patches of GFP within the tumor tissue, which
was depicted using Hoechst 33342 staining. Using X-gal
staining, functional b-galactosidase was detected in
GLV-1h68-infected tumors only and correlated with the
GFP-positive regions. Furthermore, plaques obtained
from prodrug-treated GLV-1h68-injected mice and ana-
lyzed by X-gal staining revealed that all plaques stained
positive for b-galactosidase. Therefore, prodrug treatment
did not lead to a selection of GLV-1h68 mutants with
nonfunctional b-galactosidase or to a reduction of VACV
titers in tumors.
Taken together, our data showed that a combination of
the oncolytic, lacZ-encoding VACV strain GLV-1h68
with a b-galactosidase-activatable prodrug could induce
apoptosis in breast cancer cells and led to accelerated
tumor shrinkage in a xenograft mouse model.
Discussion
In this work, the mode of action and the effects of a
combination therapy using an oncolytic VACV strain,
together with a b-galactosidase-activatable prodrug on
tumor regression, were analyzed in a breast cancer
xenograft mouse model system. The used human breast
cancer cell line GI-101A was derived from cells isolated
from a 57-year-old female cancer patient with recurrent,
infiltrating ductal adenocarcinoma.
32,33 It has been
previously shown that xenograft tumors derived from
GI-101A cells are eradicated on treatment with GLV-
1h68,
7 the onolytic VACV strain also used in this study.
Cell culture experiments revealed that GLV-1h68 as
well as the control virus strain GLV-1h43 lacking the lacZ
gene insert, both infected and replicated equally well
within GI-101A cells (Figure 1 and data not shown).
Because only functionally active enzyme leads to conver-
sion of the prodrug, it was important to analyze
the increasing b-galactosidase activity in cell lysates
and supernatants of GLV-1h68-infected GI-101A cells
(Figures 3b–d). Activation of the prodrug was achieved
by coincubation with the sterile-filtered, b-galactosidase-
containing cell lysates and supernatants, resulting in
killing of GI-101A cells (Supplementary Figure S2).
Conversely, incubation with samples obtained from
mock- or GLV-1h43-infected cells did not change overall
survival. Furthermore, the prodrug-mediated killing
observed in the presence of sterile-filtered samples proved
that the active drug does penetrate cell membranes,
suggesting that each cell in the tumor tissue may not
necessarily have to express b-galactosidase to become
eliminated by the GDEPT.
Strong synergistic effects could also be observed in the
combined prodrug and the GLV-1h68 strain treatment
using a low multiplicity of infection of 0.05 in GI-101A
cells. The prodrug itself also resulted in significant cell
inhibition at 7 days post-application when compared with
non-prodrug-treated mock- or GLV-1h43-infected cells.
Presumably, cell growth was inhibited by the cytotoxicity
of the prodrug itself, which is comparable with that of the
cytotoxicity of doxorubicin.
23 However, this unspecific
cell growth inhibition was much lower when compared
with the additive effects observed on prodrug treatment in
combination with GLV-1h68 infection. Similar results
were also obtained in other human or canine breast
cancer cell lines (data not shown). Canine breast cancer
cells were also shown to be infected and lysed with GLV-
1h68 alone.
34 The use of several breast cancer cell lines,
therefore, provided evidence for a broader application
spectrum of the combined prodrug rVACV approach. In
addition, we also performed low-light imaging with click-
beetle luciferase-expressing GI-101A-CBG and MDA-
MB-231-CBG cells (data not shown), which supported
the results obtained by MTT assays. Taken together, the
prodrug has been cleaved on GLV-1h68-mediated ex-
pression of b-galactosidase and, thus, resulted in the
release of the cytotoxic drug 2 as a seco-analog of the
antibiotic duocarmycin SA, which was found to penetrate
cell membranes and therefore caused bystander effects in
breast cancer cells in culture.
It was reported that duocarmycin SA causes sequence-
selective alkylation of N3 of adenine in AT-rich sites of
the minor groove of DNA and induces apoptosis.
27,35 The
DNA damage results in cleavage of full-length caspase-9,
subsequent activation of caspase-3 and, ultimately, cell
death.
25,26 As shown in Figure 2, apoptosis induction via
the intrinsic pathway was confirmed by the detection of
cleaved PARP, cleaved caspase-3 and the full-length
caspase-8, as well as the decrease of full-length caspase-3
and -9, in cells treated with a mixture of prodrug and
purified b-galactosidase.
Notably, it was reported that poxviruses, such as
VACV, possess a number of mechanisms counteracting
apoptosis (reviewed in Taylor and Barry
31). Specifically,
VACV-infected cells seem to be protected from the
intrinsic apoptotic pathway involving cytochrome c
release and cleavage of caspase-9.
36–40
We therefore analyzed whether the apoptotic cascade,
observed after prodrug treatment in the presence of
purified b-galactosidase, was still activated in GLV-1h68-
infected cells. Indeed, we were able to detect high amounts
of cleaved PARP in GI-101A cells treated with prodrug
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found that lower amounts of cleaved PARP were present
in controls infected with GLV-1h68 alone or with GLV-
1h43 in the presence or absence of prodrug, whereas
almost no cleaved PARP could be detected in mock-
infected cells. Consequently, rVACV infection probably
led to activation of the apoptotic pathway in some of the
infected GI-101A cells, but was much higher in
GLV-1h68-infected and prodrug-treated cells. The differ-
ence was even more pronounced when looking at cleaved
caspase-3, which could only be detected in prodrug-
treated cells expressing b-galactosidase. In conclusion,
apoptosis was not inhibited by the infecting rVACV and
caspase-9 cleavage confirmed the activation of the
intrinsic pathway.
As we could not formally exclude that only noninfected
cells underwent apoptosis because of the observed
bystander effect, prodrug-treated GI-101A cells infected
with the GLV-1h68 strain were stained with Hoechst
33342 and propidium iodide. Subsequent fluorescence
microscopy revealed condensed nuclei also in GFP-
containing, PI-negative cells (data not shown), and
therefore supported the assumption that the activated
prodrug can overcome the rVACV-mediated antiapopto-
tic mechanisms, at least in some cells. On the other hand,
cells infected with rVACV and not undergoing apoptosis
were also detected. Such cells will die of the VACV
infection and enhance viral shedding, which will
contribute to ongoing b-galactosidase production.
A similar mechanism could also explain that the titer of
VACV was not decreased significantly on prodrug
treatment in tumors of live animals (Supplementary
Figure S3a). Another explanation for this observ-
ation could be the enrichment of mutants in lacZ.
This, however, could be excluded as prodrug-treated,
GLV-1h68-infected tumors still stained positive using
X-gal (Supplementary Figure S3c). Consistently, X-gal
staining was used to confirm functional b-galactosidase
expression in plaques resulting from VACV titer analysis
of prodrug-treated tumors from GLV-1h68-injected mice
(data not shown). Finally, the applied prodrug, in
contrast to the released active drug, is not able to
penetrate cell membranes.
23 Therefore, the activation
of the prodrug occurs in the extracellular matrix of
the tumor after release of b-galactosidase from
VACV-infected (lysed) cells and does not have direct
influence on the infection process itself. As reported
earlier and illustrated in Figure 3, the b-galactosidase is
reasonably stable and remains active after cell lysis. This
is also supported by microscopic analysis of tumor
sections in which X-gal staining was positive in regions
of GFP fluorescence, which were also characterized by
low levels of actin staining and therefore lower levels of
living cells (data not shown). Furthermore, we showed
that the highest proportion of the enzyme remains in the
tumor or is inactivated or excreted after obtaining access
to the blood circulation. Otherwise, the cleavage of the
prodrug had resulted in systemic toxicity. As no sign of
malaise or weight loss was observed in prodrug-treated
mice when compared with the respective control
mice (data not shown), we concluded that the active
b-galactosidase released from the tumor was negligible.
Taken together, the injected GLV-1h68 strain could
replicate in tumors of live mice, regardless of prodrug
therapy and did not lose its necessary ability to express
functional b-galactosidase. Even more importantly,
prodrug treatment of GLV-1h68-injected mice resulted
in effects leading to additional tumor regression, although
these were in the range of the GLV-1h43 treatment.
For unknown reasons, the latter seemed to be more
efficient than GLV-1h68 regarding tumor therapy. How-
ever, prodrug treatment could not significantly enhance
the therapeutic effect, as GLV-1h43 does not encode
b-galactosidase.
On the basis of the cell culture results, we have however
expected stronger synergistic tumor regression effects in
GLV-1h68- and prodrug-injected mice. In previous
studies, two reasons, which also could apply to our
tumor model system, have already been discussed
regarding this discrepancy.
10 First, the authors suggested
that the rapid kinetics of oncolytic VACV replication
might functionally overlap with the used cytosine
deaminase/5-fluorocytosine prodrug system. This might
also apply to the b-galactosidase/prodrug combination
that we used. Second, the authors argued that adminis-
tration of 5-fluorocytosine may have inhibited the viral
replication, thus reducing the antitumoral cytotoxicity
induced by the oncolytic virus itself. This effect has
already been reported by McCart et al.,
14 which is in
contrast to our system, as we did not observe inhibition of
viral replication in prodrug-treated animals (Supplemen-
tary Figure S3a). A reason for this difference might be
extracellular activation of the b-galactosidase-activatable
prodrug. The 5-fluorocytosine, on the other hand, was
cleaved inside the VACV-infected cells. Therefore, the
generated 5-fluorouracil may have interfered with viral
replication. It would be interesting to directly compare
secreted cytosine deaminase or membrane-penetrating
b-galactosidase-activatable prodrugs using the currently
available rVACV/GDEPT approaches to evaluate the
requirements of enzyme and prodrug location in the
tumor microenvironment.
Other theoretical problems could be the stability of the
prodrug within the body and the immune response
generated by VACV. We showed that the prodrug is not
inactivated in serum containing cell culture medium;
however, we cannot formally exclude a faster breakdown
of the prodrug in vivo. The immunological effects
generated by GLV-1h68 in immunocompromized
nude mice as well as in an immunocompetent mouse
model have been described elsewhere.
34,41–45 We do not
expect immunological effects to have any influence on the
described prodrug system in our model system. One could
think about the generation of antibodies against
b-galactosidase that could inactivate the enzyme. As we
were able to show b-galactosidase activity using
b-galactosidase-activated fluorescent probes in tumors
of live mice (J Stritzker, M Hess et al., in preparation),
we think that the generation of antibodies to
b-galactosidase will not have a significant role, but might
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low concentration of b-galactosidase leaking out of the
tumor would be cleared efficiently.
The selectivity of certain VACV strains, such as deri-
vates of the Lister strain, to replicate within tumor tissues
lead to large tumor to background ratios of 410
4,
7,34
resulting in specific expression of prodrug-converting
enzymes within tumor tissues. Such ratios can hardly be
achieved by the use of tumor-specific antibodies, which
can also be linked to prodrug-activating enzymes.
Furthermore, the amount and location of functional
b-galactosidase can be controlled before addition of the
prodrug by fluorescent imaging using b-galactosidase-
dependent probes (J Stritzker and M Hess et al.,
in preparation).
Taken together, a combined treatment using gene-
directed prodrug therapy and rVACV strains such as
GLV-1h68 holds great promise for successful tumor
therapy; however, further research is needed to find and
optimize GDEPT/rVACV systems.
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